Greg Keenan - 27 Feb 2026 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Reporting relationship: SVP, Chief Medical Officer
Issuer ticker: AUPH
Reported as of: 27 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Mar 2026, 16:13:25 UTC
Prior SEC filing: 03 Feb 2026
Next SEC filing: 10 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Greg Keenan, M.D.

Key filing fact

Greg Keenan filed Form 4 for Aurinia Pharmaceuticals Inc. (AUPH) on 03 Mar 2026.

Key facts

This page summarizes Greg Keenan's Form 4 filing for Aurinia Pharmaceuticals Inc. (AUPH).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Mar 2026, 16:13.

Change

Previous filing in this sequence was filed on 03 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002044006 Primary reporting owner

Keenan Greg

Relationship: SVP, Chief Medical Officer
Address: #140, 14315 - 118 AVENUE, EDMONTON, ALBERTA, CANADA
Signature: /s/ Greg Keenan, M.D.
Signature date: 03 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AUPH transaction

Common Stock

Award

Transaction value: $0
Shares: +40,586
Change %: +33%
Price: $0.000000
Shares after: 162,518
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AUPH transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +67,870
Change %
Price: $0.000000
Shares after: 67,870
Date: 27 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 67,870
Exercise price: $13.97
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement.

Footnote F2

One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.